Novo Nordisk on Monday revealed data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares ...

Novo Nordisk's obesity drug CagriSema failed to outperform Eli Lilly's Mounjaro in the latest trial, causing a dip in Novo's ...

Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline ...

Dr Michael Mosley's son is picking up his dad's weight loss campaign with the publication of a new book. Michael Mosley was a ...

Dr Jack Mosley is an expert in weight loss drugs but says there are important things people need to know when taking them ...

Investing.com -- Novo Nordisk’s stock has dropped around 6.6% in premarket trading Monday following the release of its latest ...

New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.

It's not too often that pharmaceutical drugs become household names, but that's happening with medicines in the weight loss ...

Dr Jack Mosley worked with his mother Dr Clare Bailey Mosley to publish a book using his medical expertise and his mother's ...

Novo Nordisk said CagriSema appeared to have a safe and well-tolerated profile in the latest trial. The most common adverse events were gastrointestinal, and the vast majority were mild to moderate ...

Novo Nordisk’s CagriSema demonstrated weight loss of 15.7% in patients with both obesity and type 2 diabetes who took the ...

It seems like no matter what I do, I can't lose weight. Most of my family members struggle with their weight too. Do our ...